Human papillomavirus and human immunodeficiency virus infections: relation with cervical dysplasia-neoplasia in African women

Ruche, Guy La; You, Bruno; Mensah-Ado, Isabelle; Bergeron, Christine; Montcho, Crépin; Ramón, Rosa; Toure-Coulibaly, K.; Welffens-Ekra, Christiane; Dabis, François; Orth, Gérard

doi:10.1002/(sici)1097-0215(19980518)76:4<480::aid-ijc6>3.0.co;2-n

Cited by 85 publications

(53 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also found that HIV-1 infection was independently associated with an increase in SIL among HPV-positive women and that HIV-1 represented an important risk factor for the presence of HSIL. These findings are in agreement with other African series (La Ruche et al, 1998;Chirenje et al, 2002;Hawes et al, 2003) and with many studies in industrialised countries (Sun et al, 1997;Ahdieh et al, 2001;Moscicki et al, 2004b;Strickler et al, 2005).…”

Section: Discussionsupporting

confidence: 93%

“…Previous studies have reported a high prevalence of multiple HPV infections among HIV-infected women (Palefsky et al, 1999;Gravitt et al, 2002) which is associated with an increased risk of intraepithelial neoplasia and of cancer (Moscicki et al, 2004a;Herrero et al, 2005). As was found in other African studies (Ter Meulen et al, 1992;Chabaud et al, 1996;La Ruche et al, 1998;Bayo et al, 2002;Kay et al, 2003), HPV-16 and -18 were less common than other HR-HPV types overall, but they were involved in 64% of HSIL lesions, while 93% of women with HSIL had viruses related to the HPV-16 or HPV-18 phylogenetic groups. Therefore, administration of a bivalent HPV-16/18 vaccine in this population before they get exposed might have the potential to prevent the majority of highgrade lesions in this population, but this would need to be determined in prospective studies.…”

Section: Discussionsupporting

confidence: 53%

“…While the epidemiology of genital HPV types has been relatively better studied in Southern and Eastern African countries such as Kenya (Temmerman et al, 1999;De Vuyst et al, 2003), Malawi (Miotti et al, 1996), Mozambique (Castellsague et al, 2001), Tanzania (Mayaud et al, 2003), Uganda (Serwadda et al, 1999), and Zimbabwe (Gravitt et al, 2002;Baay et al, 2004), data from Western Africa have been scarce. The prevalence of HPV infection and associated cervical lesions have been studied in Ivory Coast (La Ruche et al, 1998) and Mali (Bayo et al, 2002), but detailed HPV types were only reported from Senegal (Xi et al, 2003), Nigeria (Thomas et al, 2004), and The Gambia (Wall et al, 2005). Prevalence rates of HPV infection ranging from 13 to 40% have been reported from low-risk or general populations of sub-Saharan African countries (Miotti et al, 1996;Temmerman et al, 1999;Castellsague et al, 2001;De Vuyst et al, 2003;Mayaud et al, 2003;Xi et al, 2003;Baay et al, 2004;Thomas et al, 2004;Wall et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

“…However, the relationships between HIV-1, HPV and squamous intraepithelial lesions (SIL) in sub-Saharan Africa are unclear. Some studies have found no association between HIV-1 and HPV (Mayaud et al, 2001), others found an association between HIV-1 and HPV, but no association between HIV-1 and SIL (De Vuyst et al, 2003), while others found a strong association between HIV-1, HR-HPV, high-grade SIL (HSIL), and cervical cancer (La Ruche et al, 1998;Chirenje et al, 2002;Hawes et al, 2003). Surprisingly, the relentless progression of the AIDS epidemic on the African continent has not been paralleled by increases in cervical cancer rates, in contrast with rates of other AIDS-linked cancers, such as Kaposi's sarcoma or non-Hodgkin's lymphomas (Parkin et al, 1999).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso

et al. 2006

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection and cervical squamous intraepithelial lesions (SILs) were studied in 379 high-risk women. Human papillomavirus DNA was detected in 238 of 360 (66.1%) of the beta-globin-positive cervical samples, and 467 HPV isolates belonging to 35 types were identified. Multiple (2 -7 types) HPV infections were observed in 52.9% of HPV-infected women. The most prevalent HPV types were HPV-52 (14.7%), HPV-35 (9.4%), HPV-58 (9.4%), HPV-51 (8.6%), HPV-16 (7.8%), HPV-31 (7.5%), HPV-53 (6.7%), and HPV-18 (6.4%). Human immunodeficiency virus type 1 (HIV-1) seroprevalence was 36.0%. Human papillomavirus prevalence was significantly higher in HIV-1-infected women (87 vs 54%, prevalence ratio ( Cervical cancer is the most frequent cancer of women in developing countries, particularly in sub-Saharan Africa (Parkin et al, 1999), and it is now well established that genital infection with certain types of human papillomavirus (HPV) causes virtually all cases of cervical intraepithelial neoplasia (CIN) and invasive cervical cancer (ICC) (Walboomers et al, 1999). The HPV types that infect the genital tract have been subdivided into low-risk (LR) types, which are principally found in nonmalignant lesions such as genital warts, and high-risk (HR) types, which are associated with the development of CIN and ICC. Human papillomavirus types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and 89 are classified as LR types, whereas types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are classified as HR types. In addition, HPV types 26, 53, and 66 are considered as probably carcinogenic (Muñoz et al, 2003).Human papillomavirus prophylactic vaccines are now being developed and promising results have been obtained with recombinant L1 capsid protein virus-like particles (VLPs). However, the current HPV vaccines target the most prevalent high-risk HPV (HR-HPV) types worldwide, namely HPV-16 and HPV-18 (Koutsky et al, 2002;Ault et al, 2004;Brown et al, 2004;Harper et al, 2004). It has been shown that crossneutralisation induced by L1 VLPs represents less than 1% of the neutralising activity induced by the dominant conformational epitope , indicating that current HPV vaccines would be able to confer only type-specific immunity. Therefore, effectiveness of these vaccines on the prevention of cancer may be lower in populations highly affected by HR-HPV types other than HPV-16 and HPV-18. Thus, it is important to document the distribution of HPV genotypes in HPV-infected women and in women with cervical neoplasia in African countries in order to assess the potential effectiveness of a bivalent HPV-16/18 vaccine.There have been few detailed studies of HPV genotypes and their association with intraepithelial lesions or ICC in sub-Saharan Africa. Available data suggest, however, a higher prevalence and wider spectrum of oncogenic HPV types compared to studies conducted elsewhere (Castellsague et al, 2001;De Vuyst et al, 2003;Mayaud et al, 2003;Clifford et al, 2005;Wall et al, 2005). Furthermore, the high backgr...

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso

et al. 2006

View full text Add to dashboard Cite

show abstract

“…In a study of 2,198 women who attended gynaecological clinics in Abidjan, Cô . te d'Ivoire, 32 HIV-positive women had a significantly higher prevalence of squamous intraepithelial lesion (SIL, OR 3.6) for low-grade SIL and 5.8 for high-grade SIL. Temmerman et al 33 reported a five-fold increased risk of high-grade SIL among 513 HIV-positive women in a family planning clinic in Kenya.…”

Section: Biological Factorsmentioning

confidence: 99%

Cervical cancer: the sub-Saharan African perspective

Anorlu¹

2008

Reproductive Health Matters

260

243

View full text Add to dashboard Cite

Cervical cancer is the second most common cancer in women worldwide and the leading cause of cancer deaths in developing countries. While incidence and mortality rates of cervical cancer have fallen significantly in developed countries, 83% of all new cases that occur annually and 85% of all deaths from the disease occur in developing countries. Cervical cancer is the most common cancer among women in sub-Saharan Africa. The incidence is on the increase in some countries. Knowledge and awareness of this disease on the continent are very poor and mortality still very high. Facilities for the prevention and treatment of cervical cancer are still very inadequate in many countries in the region. Governments in sub-Saharan Africa must recognise cervical cancer as a major public health concern and allocate appropriate resources for its prevention and treatment, and for research. Indeed, cervical cancer in this region must be accorded the same priority as HIV, malaria, tuberculosis and childhood immunisations.

show abstract